Form 4: Myriad Genetics CEO Paul Diaz Reports Departure in SEC Filing
SEC Form 4 Filing
Paul Diaz, former President and CEO of Myriad Genetics, files a Form 4 to report his departure from the company, effective April 30, 2025.
Summary
- Paul J. Diaz, previously the President and CEO and a Director of Myriad Genetics Inc., filed a Form 4 with the SEC.
- The filing indicates that Diaz is no longer serving in these roles, effective April 30, 2025.
- The filing reports Diaz directly owns 891,844 shares of Myriad Genetics common stock.
- Diaz also directly owns time-based stock options for 342,040 shares of common stock, exercisable from August 13, 2020, and expiring on August 13, 2027, with an exercise price of $13.38.
- Additionally, Diaz directly owns performance-based stock options for 339,088 shares of common stock, exercisable from August 13, 2020, and expiring on August 13, 2027, with an exercise price of $13.38.
- This Form 4 is an 'Exit' filing, indicating that Diaz is no longer subject to Section 16 reporting requirements due to his departure.
Sentiment
Score: 5
Explanation: The document itself is neutral, simply reporting a change in leadership. The impact on the company's stock price will depend on market perception of the departure and the new leadership.
Industry Context
Executive departures are common in the biotech industry, often signaling strategic shifts or personal decisions. The market will likely watch for the appointment of a successor and any changes in company strategy.
Comparison to Industry Standards
- Executive compensation and stock option grants are standard practice in publicly traded biotech companies like Myriad Genetics.
- Comparing Diaz's stock ownership and option grants to those of CEOs at similar-sized diagnostic companies (e.g., Exact Sciences, Invitae) could provide context on the magnitude of his holdings.
- Executive transitions are often compared to those of competitors to assess potential impacts on market share and innovation.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President and CEO | Paul J. Diaz | TBD | 04/30/2025 | Departure |
| Director | Paul J. Diaz | TBD | 04/30/2025 | Departure |
Stakeholder Impact
- Shareholders will be interested in the transition plan and the appointment of a new CEO.
- Employees may experience uncertainty during the leadership transition.
- Customers and partners may be concerned about potential changes in company strategy or product development.
Key Dates
| Date | Description |
|---|---|
| 08/13/2020 | Date time-based and performance-based stock options became exercisable |
| 08/13/2027 | Expiration date for time-based and performance-based stock options |
| 04/30/2025 | Effective date of Paul Diaz's departure from Myriad Genetics |
Keywords
Form 4, SEC Filing, Myriad Genetics, Paul Diaz, CEO, Departure, Stock Options, Common Stock, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.